

1  
2 UNITED STATES DISTRICT COURT  
3 DISTRICT OF NEVADA

4 SHERIF W. ABDOU, M.D. and AMIR S.  
5 BACCHUS, M.D.,

6 Plaintiffs,

7 v.

8 DAVITA INC., HEALTHCARE PARTNERS  
9 HOLDINGS, LLC, and HEALTHCARE  
PARTNERS, LLC,

10 Defendants.

11  
12 AND RELATED CLAIMS.  
13

Case No. 2:16-cv-02597-APG-CWH

**TEMPORARY RESTRAINING ORDER**

(ECF No. 65)

14 The Emergency Motion for Temporary Restraining Order and Preliminary Injunction  
15 (“Motion for TRO”) filed by defendants DaVita Inc. f/k/a DaVita HealthCare Partners Inc.  
16 (“DaVita”); Healthcare Partners Holdings, LLC (“HCP Holdings”); and DaVita Medical Nevada,  
17 LLC, f/k/a Healthcare Partners, LLC (“HCP”) (collectively, the “DaVita Parties”) came on for  
18 hearing on October 31, 2017, at 3:00 p.m.

19 **FINDINGS OF FACT**

20 Having considered the parties’ briefs, the records and documents on file, and the arguments  
21 of counsel, I make the following preliminary findings of fact:

22 1. In early 2012, DaVita and HCP entered into negotiations regarding a potential merger  
23 of the companies (the “Merger”).

24 2. On March 16, 2012, Abdou/Bacchus sued HCP Holdings and JSA Healthcare  
25 Nevada, LLC (“JSA Nevada”), a subsidiary of the DaVita Parties.

26 3. On May 20, 2012, JSA Nevada and Abdou/Bacchus entered into settlement  
27 agreements (the “2012 Settlement Agreements”).

28 4. Pursuant to the 2012 Settlement Agreements, Abdou/Bacchus: (i) received substantial

1 compensation; (ii) entered into amendments to their Employment Agreements; (iii) agreed to  
2 covenants not to compete ancillary to their employment; and (iv) agreed to covenants not to compete  
3 ancillary to the transfer of their ownership interests in HCP Holdings in connection with the Merger  
4 (the “Sale Noncompetes”).

5         5.       Abdou/Bacchus received \$15 million in compensation pursuant to the 2012  
6 Settlement Agreements. Specifically, each Plaintiff received a “Merger Transaction Settlement  
7 Payment”—Dr. Abdou received \$6 million and Dr. Bacchus received \$4 million. Further, Dr.  
8 Abdou received \$3 million and Dr. Bacchus received \$2 million as specific consideration for the  
9 Sale Noncompetes.

10         6.       On May 20, 2012, Abdou/Bacchus and DaVita entered into the Sale Noncompetes.

11         7.       Abdou/Bacchus were represented by legal counsel in negotiating the 2012 Settlement  
12 Agreements and the Sale Noncompetes.

13         8.       In entering into the Sale Noncompetes, Abdou/Bacchus expressly acknowledged that:

14                 a.       They were selling their ownership interest in HCP Holdings as part of the  
15 Merger transaction;

16                 b.       The Sale Noncompetes were a condition precedent to the Merger, “a material  
17 inducement to [DaVita] to consummate the transactions contemplated in the Merger Agreement,”  
18 and that DaVita “would be unwilling to consummate such transactions if [Abdou/Bacchus] did not  
19 enter into [the Sale Noncompetes][;]”

20                 c.       The Sale Noncompetes were necessary to protect the benefits and value that  
21 DaVita would acquire through the Merger. Specifically, Abdou/Bacchus expressly acknowledged  
22 that, “due to [their] affiliation with [HCP Holdings],” they had “acquired intimate knowledge of, and  
23 experience related to, the business of the [HCP Holdings] and [DaVita], which, if exploited by  
24 [Abdou/Bacchus] in contravention of this Agreement, would seriously, adversely and irreparably  
25 affect the ability of [DaVita] and its Affiliates . . . to derive the benefit or value for which it  
26 bargained in the Merger Agreement.”

27                 d.       That any breach of the Sale Noncompetes “would cause irreparable injury to”  
28 DaVita and its subsidiaries and that they “shall be entitled to enforce” the Sale Noncompetes “by

1 demanding specific performance and immediate injunctive relief as remedies for such breach or any  
2 threatened breach.”

3 9. The Sale Noncompetes expressly prohibit Abdou/Bacchus from “directly or  
4 indirectly” engaging in or preparing to engage in (or having any interest in, or providing any  
5 assistance to, any entity or group that is engaging in or preparing to engage in) a “Restricted  
6 Business” in Nevada, California, Florida, or New Mexico (the “Restricted Region”) for five (5)  
7 years from the closing date of the Merger (the “Restricted Period”). The Restricted Region is  
8 composed of states where the DaVita Parties continue to conduct their business operations.

9 10. Under the Sale Noncompetes, “Restricted Business” is defined to capture the type of  
10 services which Abdou/Bacchus provided to HCP—management of physician practices and  
11 organizations involved in population health management services, including:

12 a. “Physician practices, independent physician associations or any other form of  
13 practicing physician organization;”

14 b. “[O]rganizations engaged in coordinated care, managed care, accountable care  
15 and other similar models of care for a population of patients; [“Population Health  
16 Management”];”

17 c. “[O]rganizations which provide management or related services to  
18 organizations described in [(a) or (b)];”

19 d. “[H]ospitals, [Accountable Care Organizations], HMOs or other licensed  
20 health plans, but only insofar as [Abdou/Bacchus’s] role (A) would include activities on  
21 behalf of such organizations described in [(a), (b), or (c)], including, but not limited to,  
22 having direct responsibility for or having direct influence in setting up, running, management  
23 or controlling a provider network; or (B) would include engaging in direct negotiations or  
24 consulting on negotiations on behalf of such organization with [DaVita] or its Subsidiaries . .  
25 . .;” and

26 e. “[A]ssisting any third party to engage in [(a)] through (d)].”

27 11. The Sale Noncompetes expressly allow each Plaintiff to “personally [practice]  
28 medicine as a physician” and leave open many other types of work in the healthcare field.

1           12.     The Sale Noncompetes contain a tolling provision that provides “the Restricted  
2     Period shall be tolled during any period that [Abdou/Bacchus are] in breach of the terms of” the Sale  
3     Noncompetes.

4           13.     The closing date of the Merger was November 1, 2012. Accordingly, in the absence  
5     of any violations, the Sale Noncompetes would have expired on their own terms on November 1,  
6     2017.

7           14.     Some of the documents produced in discovery by Abdou/Bacchus on October 16,  
8     2017 (the “Abdou/Bacchus Documents”)<sup>1</sup> indicate that Abdou/Bacchus personally and through the  
9     companies that they own and control—P3 Health Group Holdings, LLC; P3 Health Group LLC; P3  
10    Health Group Management, LLC; and P3 Health Partners (collectively, “P3 Health”)—participated  
11    in meetings, discussions, negotiations, and strategy sessions with Anthem Inc. (“Anthem”), Humana  
12    Inc. (“Humana”), and Universal Health Services, Inc. (“UHS”) from as early as January 15, 2016  
13    through at least August 9, 2017, to engage in a Restricted Business in Nevada (a Restricted Region),  
14    including specific discussions and strategy sessions on actions that could be taken to adversely affect  
15    and displace the DaVita Parties’ business operations in the Nevada healthcare market.

16          15.     The DaVita Parties filed an Emergency Motion for Temporary Restraining Order and  
17    Preliminary Injunction (“Motion for TRO”) on October 24, 2017; Abdou/Bacchus filed their  
18    response on October 29, 2017; and the DaVita Parties submitted their reply in support of the Motion  
19    for TRO on October 31, 2017. I held a hearing on October 31, 2017. ECF No. 76.

#### 20                                   **CONCLUSIONS OF LAW**

21          1.       “A plaintiff seeking a preliminary injunction must establish [1] that he is likely to  
22    succeed on the merits, [2] that he is likely to suffer irreparable harm in the absence of preliminary  
23    relief, [3] that the balance of equities tips in his favor, and [4] that an injunction is in the public  
24    interest.” *Winter v. Nat. Res. Def. Council, Inc.*, 555 U.S. 7, 24 (2008). “Temporary restraining  
25  
26  
27

---

28    <sup>1</sup> See ECF Nos. 67-2 through 67-9.

1 orders are governed by the same standard applicable to preliminary injunctions.” *Quiroga v. Chen*,  
2 735 F. Supp. 2d 1226, 1228 (D. Nev. 2010).

3 2. The DaVita Parties have demonstrated a likelihood of success on the merits. I  
4 preliminarily find that Abdou/Bacchus engaged in a Restricted Business in the Restricted Region  
5 during the Restricted Period based on their activities with Anthem, Humana, and UHS (as evidenced  
6 by the Abdou/Bacchus Documents), which constitutes a breach of the Sale Noncompetes.

7 3. The DaVita Parties are likely to suffer irreparable harm unless a temporary restraining  
8 order issues.

9 a. Abdou/Bacchus expressly recognized that, “due to [their] affiliation with”  
10 HCP, they “acquired intimate knowledge of, and experience related to, the business of [HCP  
11 Holdings] and [DaVita] which, if exploited by [Abdou/Bacchus] in contravention of the [Sale  
12 Noncompetes], would seriously, adversely, and irreparably affect the ability of [DaVita] and its  
13 Affiliates . . . to derive the benefit or value for which it bargained in the Merger Agreement.”

14 b. Abdou/Bacchus expressly agreed that any breach of the Sale Noncompetes  
15 “would cause irreparable injury” to DaVita and their subsidiaries (including HCP) and would entitle  
16 them to “immediate injunctive relief as remedies for such breach . . . .”

17 c. The goodwill paid for by the DaVita Parties was a material and important  
18 aspect of the Merger, and they are entitled to the protections of the Sale Noncompetes for the  
19 Restricted Period. Allowing Abdou/Bacchus to exploit information, experience, and relationships  
20 they obtained while they were executives at HCP (e.g. relationships with Anthem, Humana, and  
21 UHS) during the Restricted Period deprives the DaVita Parties of the opportunity to build and  
22 maintain such relationships with those third parties (such as Anthem, Humana, and UHS) and  
23 interferes with the DaVita Parties’ relationships with third parties—damaging the goodwill for which  
24 the DaVita Parties paid Abdou/Bacchus substantial consideration in the Merger.

25 4. The balance of the equities tilts in favor of the DaVita Parties. In the absence of  
26 injunctive relief the DaVita Parties will suffer irreparable harm. Conversely, Abdou/Bacchus will  
27 not suffer any harm during the pendency of this temporary restraining order. Abdou/Bacchus  
28 represented to the court at the hearing that no deal with Anthem, Humana, or UHS was imminent.

1 Thus, a short extension of the Sale Noncompetes with respect only to Anthem, Humana, and UHS  
2 would not harm Abdou/Bacchus pending resolution of the motion for a preliminary injunction.

3 5. Temporarily enforcing the Sale Noncompetes within the narrowly tailored parameters  
4 set forth below is in the public interest as the public has an interest in protecting the freedom of  
5 persons to contract.

6 6. As Abdou/Bacchus will suffer no harm due to this Temporary Restraining Order, no  
7 bond is necessary.

### 8 **ORDER**

9 1. IT IS HEREBY ORDERED that the Motion for TRO (**ECF No. 65**) is **GRANTED**,  
10 and that a Temporary Restraining Order shall issue in favor of the DaVita Parties.

11 2. IT IS FURTHER ORDERED that Abdou/Bacchus as well as their officers, directors,  
12 agents, servants, employees, attorneys, and those persons in concert or participation with them who  
13 receive actual notice of this Temporary Restraining Order by personal service or otherwise, are  
14 hereby enjoined from engaging in any of the following activities insofar as such activities are done  
15 in connection with or otherwise relate, directly or indirectly, to Anthem, Humana, or UHS (or any of  
16 their affiliates, agents, employees, or subsidiaries; e.g. Prominence Health Plan):

- 17 • Take any action that results or may reasonably be expected to result in owning, leasing,  
18 managing, operating, joining, extending credit to, controlling or participating in the  
19 ownership, leasing, management, operation, extension of credit to, or control of, whether as  
20 an employer, shareholder, employee, director, manager, lender, joint venture, member,  
21 consultant, advisor or partners, whether or not compensated for any of the foregoing, with  
22 any business that, directly or indirectly anywhere within Nevada, California, Florida, and  
23 New Mexico, engages in or derives any economic benefit from, or is preparing to engage in  
24 or service any economic benefit from, the Restricted Business (as defined below); or
- 25 • For his own account or for the account of others, own, manage, operate, join, control or  
26 participate in the ownership, management, operation or control of, or be connected as an  
27 employer, shareholder, employee, director, manager, lender, joint venture, member,  
28 consultant, advisor or partner, whether or not compensated for any of the foregoing, with any

1 business that, directly or indirectly anywhere within Nevada, California, Florida, and New  
2 Mexico engages in, or takes affirmative action to prepare to engage in or derive economic  
3 benefit from, the Restricted Business.

4 • “Restricted Business” means any of the following:

- 5 i. Physician practices, independent physician association or any other form of practicing  
6 physician organization;
- 7 ii. organizations engaged in coordinated care, managed care, accountable care and other  
8 similar models of care for a population of patients;
- 9 iii. organizations which provide management or related services to organizations  
10 described in (i) or (ii);
- 11 iv. hospitals, ACOs, ancillary service providers, HMOs or other licensed health plans,  
12 but only insofar as Abdou/Bacchus’s role (A) would include activities on behalf of  
13 such organization described in (i), (ii), or (iii), including but not limited to, having  
14 direct responsibility for or having direct influence in setting up, running, managing or  
15 controlling a provider network; or (B) would include engaging in direct negotiations  
16 or consulting on negotiations on behalf of such organization with Davita or its  
17 Subsidiaries (including HCP Holdings);
- 18 v. Dialysis Services or Renal Care Services (as defined herein), except to the extent that  
19 such services are only an incidental part of the services provided by the organization  
20 for which Abdou/Bacchus is providing services. “Dialysis Services or Renal Care  
21 Services” shall mean all dialysis services and nephrology-related services provided by  
22 Davita at any time during the period of Abdou/Bacchus’ employment, including, but  
23 not limited to, hemodialysis, home hemodialysis, dialysis-related laboratory and  
24 pharmacy services, access-related services, drug purchasing, drug distribution,  
25 Method II dialysis supplies and services, nephrology practice management, vascular  
26 services, disease management services, pre-dialysis education, ckd services, or renal  
27 physician/dent network management, and any other services of treatment for persons  
28 diagnosed as having end state renal disease or pre-end stage renal disease, including



1 any dialysis services provided in an acute hospital;

2 vi. researching, developing, marketing, or working on any products or providing any  
3 services, including direct primary care services, for a direct competitor of Direct  
4 Primary Care Holdings, LLC dba Paladina Health, or any of its subsidiaries. Direct  
5 competitors are those entities providing comprehensive primary healthcare services to  
6 patients for a recurring fee rather than individually itemized fixed fees for services for  
7 primary care services; and/or

8 vii. assisting any third party engage in (i) through (vi).

9 Notwithstanding the foregoing, nothing herein shall prohibit [Abdou/Bacchus] from  
10 personally practicing medicine as a physician.

11 3. IT IS FURTHER ORDERED that this Temporary Restraining Order shall expire at  
12 the conclusion of the preliminary injunction hearing on November 17, 2017, unless otherwise  
13 extended by this Court.

14  
15   
16 UNITED STATES DISTRICT JUDGE

17 Date this 14th day of November at 12:45 p.m.,  
18 nunc pro tunc to October 31, 2017 at 5:07 p.m.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28